Get Live Data

The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. Synairgen Share Price
  4. Synairgen Share Regulatory News
  5. Holding(s) in Company

Pin to quick picksSynairgen Regulatory News (SNG)

Synairgen Information

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 Mar 2022 16:35

RNS Number : 0818E
Synairgen plc
08 March 2022
 

 

Synairgen plc

 

("Synairgen" or the "Company")

 

Holding(s) in Company

 

Synairgen was informed on 8 March 2022 that Polar Capital LLP no longer has a disclosable interest in the Company.

 

For further information, please contact:

 

Synairgen plc 

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Brooke Clarke, Head of Communications

Tel: +44 (0) 23 8051 2800

 

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: +44 (0) 20 7220 0500

 

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: +44 (0) 20 7260 1000

 

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

 

MK Strategies, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com

Tel: +1 516 606 6545

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFVRVLITIIF
12345678910
Date   Source Headline
8th Dec 20117:00 amRNSEnd of Recruitment in Phase II Asthma Trial
25th Nov 20117:00 amRNSPositive Viral Pneumonia Study Results
10th Nov 201112:40 pmRNSResult of AGM
18th Oct 20111:50 pmRNSNotice of AGM and posting of Annual Reports
22nd Sep 20113:10 pmRNSGrant of options
9th Sep 20117:00 amRNSChange of Adviser
18th Jul 20117:00 amRNSJapanese Patent to be Granted
28th Jun 20117:00 amRNSPhase II asthma study - Interim Review and update
15th Jun 20113:56 pmRNSHolding(s) in Company
13th Jun 201111:54 amRNSResult of General Meeting
27th May 20111:00 pmRNSFundraising
4th May 20117:00 amRNSAntiviral activity against Bird Flu
2nd Feb 201111:31 amRNSHolding(s) in Company
1st Feb 20117:00 amRNSHalf Yearly Report
3rd Nov 20101:35 pmRNSResult of AGM
19th Oct 20107:00 amRNSUS Patent
8th Oct 20109:00 amRNSNotice of AGM and Posting of Annual Report
9th Sep 20107:00 amRNSGrant of Options
29th Jul 20107:00 amRNSFinal Results
27th Jul 20107:00 amRNSNotice of Results
29th Jun 20107:00 amRNSGrant of Options
28th Jun 20107:00 amRNSDirectorate Change
17th May 20107:00 amRNSPositive Influenza Data
6th May 20107:00 amRNSIFN-beta Patent Granted in Europe
1st Apr 20107:00 amRNSPhase II Trials
24th Feb 20103:27 pmRNSHolding(s) in Company
8th Feb 20107:00 amRNSHalf Yearly Report
15th Jan 20107:00 amRNSHolding(s) in Company
12th Nov 20097:00 amRNSSuccessful Outcome of Phase 1 Study
11th Nov 20091:24 pmRNSResult of AGM
9th Nov 20097:00 amRNSactivity of interferon beta against swine flu
26th Oct 20097:00 amRNSNotice of Investor Conference
14th Oct 20092:35 pmRNSNotice of Annual Report and Accounts and AGM
8th Sep 200911:25 amRNSGrant of Options
4th Sep 20097:00 amRNSFinal Results
4th Sep 20097:00 amRNSUS Patent Granted
4th Sep 20097:00 amRNSDirectorate Changes
2nd Sep 20097:00 amRNSNotice of Results
17th Jul 20093:00 pmRNSHolding(s) in Company
30th Jun 20099:56 amRNSTotal Voting Rights
25th Jun 20092:36 pmRNSHolding(s) in Company
23rd Jun 20097:00 amRNSHolding(s) in Company
15th Jun 200911:06 amRNSSecond Closing of the Fundraising
12th Jun 200911:22 amRNSResult of General Meeting
27th May 20097:00 amRNSFundraising Announcement
1st Apr 20097:00 amRNSPreliminary biomarker data
31st Mar 20097:00 amRNSChange of Adviser
26th Mar 20097:00 amRNSHalf Yearly Results
24th Mar 200911:14 amRNSNotice of Results
17th Mar 20097:00 amRNSProgress update: Clinical Trial - Interferon Beta
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.